BioMultiDeTeC
BioMultiDeTeC
BioMultiDeTeC is an R&D&I project developed within the framework of the Science and Innovation Missions Programme 2024, aimed at the development of new biosanitary technology for the early detection of breast cancer through liquid biopsy. The project investigates an innovative diagnostic solution based on a multi-analytical biosensor capable of simultaneously detecting different types of tumor biomarkers, with the objective of improving accuracy, sensitivity, and early anticipation of clinical diagnosis, thereby contributing to a more personalized, efficient, and minimally invasive medicine.
- Project name: BioMultiDeTeC
- Acronym: BIOMULTIDETEC
- Programme: Science and Innovation Missions Programme 2024. Project funded by the European Union – NextGenerationEU, within the framework of the Recovery, Transformation and Resilience Plan, through CDTI.
- Mission: Mission 6 – Digital Health
- Full title: New multi-analytical biosensor technology for the early detection of breast cancer through liquid biopsy
- Implementation period: 07/09/2024 – 31/12/2025
- Total budget: 1,523,994.00 €
- Total grant: 1,107,388.56 €
- Mecwins budget: 611,478.85 €
General objective:
To develop a disruptive biosanitary technology that enables the early detection of breast cancer through liquid biopsy by integrating, within a single system, the simultaneous detection of circulating tumor cells, protein tumor biomarkers, and microRNAs, thereby improving the sensitivity and specificity of clinical diagnosis.
Specific objectives:
- To investigate new polymeric sensing surfaces compatible with liquid-phase analysis.
- To develop optimized nanoparticles for multiplexed detection.
- To integrate the detection of CTCs, HER2, and microRNAs into a single biosensor cartridge.
- To design an advanced AVAC-based reading prototype adapted for liquid biopsy applications.
- To validate the technology using real patient samples.
This multidisciplinary consortium combines the expertise of Mecwins in developing high-precision technologies for biomarker detection with the specialization of Destina Genomica in nucleic acid testing and advanced diagnostic assays.
Collaborating entities:
- Digitalisation of healthcare;
- Early diagnosis;
- Biomedical innovation;
- Sustainability and reduction of invasive procedures.
